3 Momentum Stocks That Could Soar Post-Market Volatility Certara (NASDAQ:CERT) executives outlined the company’s strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies’ 2026 Global Healthcare Conference, with newly…
pointed Chief Executive Officer Jon Resnick saying the company is focused on creating clearer growth engines and improving execution. Resnick, who said he started as CEO on Jan. 1, described the first several months as “pretty active” and said Certara has been speaking with customers, regulators and internal teams about growth opportunities
He said the company’s mission is to “disrupt clinical trials” or “transform clinical trials, clinical development for good.” Certara Reorganizes Around ACE and MID3 – Simulations Plus Stock Drops 15% Despite EPS Beat Resnick said Certara has realigned around two strategic growth engines: ACE, or accelerating clinical evidence, and MID3, or model-informed drug development and discovery. ACE is focused on helping clients manage data “from protocol to submission,” improve efficiency and unlock data more quickly, Resnick said. He cited Certara assets including Phoenix, Pinnacle, CoAuthor and GlobalSubmit as part of that effort. – Are These 3 Small Momentum Stocks Setting Up Big Gains?
MID3, which Resnick said is the area Certara is “probably best known for,” is focused on using computational biology and biosimulation to change how clinical development is conducted. He said the company sees growth opportunities in discovery, where it has made significant investment. Asked about Phoenix, Resnick said the product has “two distinct applications.” One component is a computational engine tied to PK/PD and population pharmacokinetic analysis, while another broader application suite is focused on data management and computational mechanics.